Descripción de la empresa
Alumis Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of therapeutic agents specifically targeting autoimmune disorders. This specialized focus positions the firm within the broader Healthcare sector, functioning under the Biotechnology industry where innovation in drug discovery and clinical trials defines the competitive landscape. The company demonstrates a substantial market capitalization of $3.15 billion, supported by a reported annual revenue of $24.05 million and an organizational workforce of 221 employees. These valuation and revenue figures, combined with a significant cash reserve, indicate that the market assigns a high premium to Alumis's pipeline assets, suggesting investors value the potential future commercialization of its drug candidates more highly than the current revenue generation capabilities, which is typical for early-stage biopharmaceutical firms.
Salud financiera
The financial performance metrics reveal a revenue of $24.05 million over the trailing twelve months, contrasted against a net income of -$243,324,992 and an EBITDA of -$438,408,000. The substantial negative gap between the positive revenue and the deeply negative net income highlights an aggressive cost structure characterized by high research and development expenditures that absorb all operating profits. The company generated free cash flow of -$202,334,000, indicating a net outflow of cash that limits immediate financial flexibility but is often a necessary condition for funding clinical trials in the biotechnology sector. Margin analysis shows a gross margin of 100.0%, reflecting a cost of goods sold of zero, while the operating margin stands at -5067.1% and the profit margin at 0.0%, illustrating that overhead costs and R&D expenses significantly exceed gross profit generation. Regarding leverage, the company holds $308.50 million in cash against $36.91 million in debt, resulting in a debt-to-equity ratio of 12.25, which suggests a highly leveraged balance sheet relative to equity but mitigated by significant cash holdings. The current ratio is 4.34, a figure that indicates robust short-term liquidity and a strong ability to meet obligations with its current assets. Finally, the return on equity is -86.7% and the return on assets is -73.4%, metrics that reveal that management is currently generating negative returns on the capital base due to the pre-revenue nature of the business model.
Evaluación de valoración
Valuation multiples for Alumis Inc. include a P/E ratio (TTM) that is N/A and a forward P/E of -7.84, a discrepancy that implies earnings are currently negative while the forward metric accounts for anticipated future profitability adjustments. The price-to-book ratio is 8.62, indicating that the market values the company at a significant premium over its tangible book value, likely driven by the intangible value of its intellectual property and pipeline. Alternative valuation metrics such as the price-to-sales ratio of 131.17 and an EV/EBITDA of -6.58 suggest that traditional earnings-based valuation is not applicable, forcing reliance on sales multiples that reflect the high growth potential expected from the drug development pipeline. The stock's trading range is defined by a 52-week high of $30.60 and a 52-week low of $2.76, placing the current price within a highly volatile band typical for small-cap biotech stocks with substantial beta exposure to market sentiment. The beta value is N/A, meaning volatility relative to the broader market cannot be quantified with a standard coefficient, yet the wide spread between the high and low implies significant price sensitivity to clinical trial outcomes and market conditions.
Growth & Income
Growth metrics for Alumis Inc. show revenue growth (YoY) as N/A and earnings growth (YoY) as N/A, reflecting the company's status as a pre-revenue or early-revenue entity where historical growth rates are not yet established. As the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings and cash flows are reinvested directly into research, development, and clinical expansion rather than being returned to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceutical firms that prioritize funding the advancement of their drug candidates, such as envudeucitinib and A-005, over providing income to investors. Consequently, the overall growth and income profile is characterized by zero current income generation and a total focus on capital deployment toward future commercialization milestones rather than short-term financial returns or dividend payments.